Drugs / SYS6023
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07110883 | Aug 2024 → Oct 2026 expected | neoplasm | CSPC Megalith Biopharmaceutical Co.,Ltd. | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07597629 | May 2026 → Nov 2027 expected | breast cancer | CSPC Megalith Biopharmaceutical Co.,Ltd. | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SYS6023 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07597629 ↗ |
| Modality | Other / unclassified | “novel antibody-drug conjugate (ADC)” NCT07110883 ↗ |
| Route | Intravenous | “administered via intravenous infusion” NCT07110883 ↗ |
| Target | ERBB3 | “targeting HER3” NCT07597629 ↗ |